Since elevated MYBL2 is commonly observed in carcinomas with HR defects and combined TP53 and RB1 genetic alterations, our study supports the use of CHK inhibitors for other carcinomas, including small cell lung cancer. This evidence concerns the gene TP53 and carcinoma.